GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transcenta Holding Ltd (HKSE:06628) » Definitions » Change In Working Capital

Transcenta Holding (HKSE:06628) Change In Working Capital : HK$0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Transcenta Holding Change In Working Capital?

Transcenta Holding's change in working capital for the quarter that ended in Dec. 2024 was HK$0.00 Mil.

Transcenta Holding's change in working capital for the fiscal year that ended in Dec. 2024 was HK$-39.68 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Transcenta Holding Change In Working Capital Historical Data

The historical data trend for Transcenta Holding's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transcenta Holding Change In Working Capital Chart

Transcenta Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Working Capital
Get a 7-Day Free Trial -24.50 66.54 100.63 33.06 -39.68

Transcenta Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Change In Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Transcenta Holding Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows Fiscal Years EndedJanuary 31,(Amounts in millions)
Cash flows from operating activities: 2014 2013 2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net (566) (614) (796)
Inventories (1,667) (2,759) (3,727)
Accounts payable 531 1,061 2,687
Accrued liabilities 103 271 (935)
Accrued income taxes (1,224) 981 994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transcenta Holding Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Transcenta Holding's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Transcenta Holding Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transcenta Holding Ltd (HKSE:06628) » Definitions » Change In Working Capital
Comparable Companies
HKSE:02126 HKSE:02185 HKSE:09939 HKSE:02496 HKSE:02898 HKSE:00690 HKSE:01244 HKSE:02257 HKSE:02197 HKSE:02137 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
218 Xinghu Street, B6-501, Biobay, Suzhou, CHN, 215123
Website
https://www.transcenta.com
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capacities in discovery, research, development, manufacturing, and business development. It is developing approximately fifteen therapeutic antibody molecules for oncology and selected non-oncology indications, including bone and kidney disorders. The company's drug development pipeline includes Osemitamab (TST001), TST002 (Blosozumab), TST003, TST006, MSB2311, MSB0254, TST808, and others to treat various oncology and non-oncology complications in different ways. Geographically, the company operates in China (the PRC), which is its key revenue market, and the United States of America.
Executives
Qian Xueming 2101 Beneficial owner
Shi Xiaohong 2501 Other
Lav Corporate Gp, Ltd. 2201 Interest of corporation controlled by you
Lav Gp Iii, L.p. 2201 Interest of corporation controlled by you
Lav Biosciences Fund Iii, L.p. 2101 Beneficial owner
Shi Yi 2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited
Tls Beta Pte. Ltd.
Hsbc Trust Company (delaware), N.a. 2301 Trustee
Success Link International L.p. 2101 Beneficial owner
Temasek Holdings (private) Limited
Lav Vitality Limited 2101 Beneficial owner
Zhong Guo Guo You Qi Ye Jie Gou Tiao Zheng Ji Jin Gu Fen You Xian Gong Si 2501 Other

Transcenta Holding Headlines

No Headlines